Assessing the efficacy of highly active antiretroviral therapy in the brain

Brain Pathology

Volumn 13, Issue 1, 2003, Pages 104-110

  Kandanearatchi, Apsara ^a   Williams, Brenda ^a   Everall, Ian Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN INFECTION; CEREBROSPINAL FLUID; CONFERENCE PAPER; DEMENTIA; DRUG CEREBROSPINAL FLUID LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SURVIVAL; VIRUS LOAD; VIRUS REPLICATION;

EID: 0037246672     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2003.tb00011.x     Document Type: Conference Paper

References (74)

1. Arendt G, Giesen HJ, Hefter H, Theisen A (2001) Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. AIDS 15:493-500.
2. Asare E, Dunn G, Glass J, McArthur J, Luthert P, Lantos P, Everall I (1996) Neuronal pattern correlates with the severity of HIV-associated dementia complex: usefulness of spatial pattern analysis in clinico-pathological studies. Am J Pathol 148:31-38.
3. Bacheler LT, Anton E, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang X, Ellis D, Becker M, Lasut A, George H, Spalding D, Hollis G, Ambremski K (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents and Chemotherapy 44:2475-2484.
4. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Pomerantz C (1996) Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by combination of in situ PCR and immunohistochemistry. AIDS 10:573-585.
5. Bell JE, Brettle RP, Chiswick A, Simmonds P (1998) HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS effect of neocortical involvement. Brain 121:2043-2052.
6. Bouwman FH, Skolasky RL Hes D, Seines OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998) Variable progression of HIV associated dementia. Neurology 50:1814-1820.
7. Brady K, Aldrich J, Broston R, MacGregor RR (1998) Stavudine entry into cerebrospinal fluid of HIV-infected subjects after single and multiple doses. 12th World AIDS Conference, Poster session 2355.
8. Brew BJ, Bhalla RB, Fliesher, Paul M, Khan A, Schwartz MK, Price (1989) Cerebrospinal fluid B2 microglobulin n patients infected with human immunodeficiency virus. Neurology 39:830-834.
9. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW (1990) Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 28:556-560.
10. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho E-S, Cornblath MC, Dal Canto MC, DeGirolami U, Dickson D, Epstein LG et al (1991) HIV-related disease of the nervous system: A glossary and proposal for neuropathology-based terminology. Brain Pathol 1:143-150.
11. Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CHW, Bult A, Beijnen JH (1993) Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 7:1581-1587.
12. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravicik S, Maurath C (1998) Randomised placebo-controlled trail of ritonavir in advanced HIV-1 disease. Lancet 351:543-549.
13. Cashion MF, Banks WA, Bost KL, Kastin AJ (1999) Transmission routes of HIV-1 gp120 from blood to lymphoid tissues. Brain Research 822:26-33.
14. Cheng-Meyer C, Levy J (1988) Distinct biological and serological properties of HIV isolates from the brain. Ann Neurol 23:S58-S61.
15. Cheng-Meyer C, Levy J (1990) Human immunodeficiency virus infection of the CNS: characterisation of the neurotropic strains. Current Topics Microbial Immunology 160:145-156.
16. Clifford DB (1998) Antiretroiral therapies for HIV infection implications for treatment of neurologic manifestations: An overview. In: Neurology of AIDS. Chapter 24, p.353-363.
17. Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter C (2001) Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV infected women. AIDS 15:341-345.
18. Deeks SG, Wrin TW, Lieger T, Hoh R, Hayden M, Barbour JD, Hellman NS, Petropoulos J, McCune JM, Hellerstein MK, Grant R (2001) Virological and immunological consequences of discontinuing combination antiretroviraldrug therapy in HIV-1 infected patients with detectable viremia. N Engl J Med 344:472-480.
19. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes in AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13:1249-1253.
20. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA and the HNRC Group (1997) Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42:679-688.
21. Egger M (1998) Opportunistic infections in the era of HAART. XII International Conference in AIDS, Geneva (abstract 76).
22. Egger M, Hirschel B, Francioli P (1997) Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. British Med J 315:1194-1195.
23. Enzensberger W, von Giesen HJ (1999) Antiretroviral therapy (ART) from a neurological point of view. German Neuro-AIDS study Group (DNAA). Eur J Med Res 4:456-462.
24. Everall IP, Luthert PJ, Lantos PL (1991) Neuronal loss in the frontal cortex in HIV infection. Lancet 337:1119-1121.
25. Everall IP, Luthert P, Lantos P (1993) A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanisms and relationship to dementia. J Neuropathol Exp Neurol 52:561-566.
26. Fox E, Bungay PM, Bacher J, McCully CL, Dedrick RL, Balls FM (2002) Zidovudine concentratin in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharm and Exp Therap 301:1003-1011.
27. Foudraine NA, Hoetelmans RMW, Lange JMA, de Wolf F, van Benthem BHB, Maas JJ, Keet IPM, Portegies P (1998) Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine and stavudine. Lancet 351:1547-1551.
28. Gelman BB, Guinto FC (1992) Morphometry, histopathology and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. Ann Neurol 32:31-40.
29. Gibb JE, Thomas SA (2002) The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-404.
30. Gisslen M, Norkrans G, Svennerholm B, Hagberg L (1997) The effect on cerebrospinal fluid HIV RNA levels after initiation of zidovudine or didanosine. J Infect Dis 175:434-437.
31. Glass JD, Fedor H, Wesseling SL, McArthur JC (1995) Immunocytochemical quantitation of the human immunodeficiency virus in the brain: Correlations with dementia. Ann Neurol 38:755-762.
32. Gray F, Belec L, Keohane C, De Truchis P, Clair B, Durigon M, Sobel A, Gherardi R (1994) Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 8:489-493.
33. Groothuis DR, Levy RM (1997) The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 3:387-400.
34. Gulick RM, Mellrs J, Havlir D, Eron J, Gonzalez C, McMahon D, Richman D, Valentine F, Jona L, Meibohm A, Emini E, Chodakewitz J (1997) Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739.
35. Haworth SJ, Christofalo B, Anderson RD, Dunkle LM (1998) A single dose-study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J AIDS Res Hum Retrovirol 17:235-238.
36. Hervey PS, Perry CM (2000) Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60:447-479.
37. Husstedt I, Frohne L, Bockenholt S, Frese A, Rahmann A, Heese C, Reichelt D, Evers S (2002) Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: Cross-sectional and longitudinal studies of event-related potentials. AIDS Res Hum Retrovir 18:485-490.
38. Jernigan TL, Archibald S, Hesselink JR, Atkinson JH, Velin RA, McCutchan JA, Chandler J, Grant I (1993) MRI morphometric analysis of cerebral volume loss in HIV infection. Arch Neurol 50:250-255.
39. Joly V, Yeni P (1999) Non nucleoside reverse transcriptase inhibitors. AIDS Rev 1:37-44.
40. Kandanearatchi A, Zuckerman M, Smith M, Vyakarnam, Everall IP (2002) Granulocyte-macrophage colony-stimulating factor enhances viral load in human brain tissue: amelioration with stavudine. AIDS 16:413-420.
41. Kandanearatchi A, Trillo-Pazos G, Vyakarnam A, Everall IP (2000) Zidovudine and abacavir prevents neuronal loss in a HIV infected human brain aggregate system. 7th European Conference on Experimental AIDS Research, Genoa, Italy.
42. Kearney B, Price R, Sheiner et al (1999) Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, Abstract 406.
43. Latendre SL, Ellis R, McCutchan J (2000) Antiretroviral therapy (ART) induces changes in chemokines that correlate with improvements in cognitive function and HIV RNA. 7th Conference on Retroviruses and Opportunistic Infections.
44. Limoges J, Persidsky Y, Poluektova L, Rasmussen J, Ratanasuwan W, Zelivyanskaya M, McClermon DR, Lanier ER, Gendelman HE (2000) Evaluation of anti-retroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 54:379-389.
45. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan A, Nelson JA, Atkinson JH, Grant I and HNRC Group (1997) Dendritic injury is a pathological substrate for HIV related cognitive disorders. Annals Neurology 42:963-972.
46. Masliah E, Ge N, Achim C, Hansen LA and Wiley CA (1992) Selective vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51:585-593.
47. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Claire M, Lanier ER (1997) Relationship between human immunodeficiency virus associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42:689-698.
48. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NMH, McArthur JH, Selnes OA, Jacobson LP, Visscher BR, Concha M, Saah A (1993) Dementia in AIDS patients: incidence and risk factors. Neurology 43:2245-2252.
49. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS (1999) Pharmacokinetics of [14C] Abacavir, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, administered in a single oral dose to HIV-1 infected adults: a mass balance study. Antimicrob Agents Chemother 43:2855-2861.
50. Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Derereux H, Dayton J, Dykhoff A, Lipman MC, Phillip AN, Johnson MA (1999) Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J AIDS 21:401-407.
51. Navia BA, Cho ES, Petito CK, Price RW (1986) The AIDS dementia complex. Ann Neurol 19:525-535.
52. Nouvo GJ, Gallery F, MacConnell P, Braun A (1994) In situ detection of polymerase chain reaction -amplified HIV-1 nucleic acids and tumour necrosis factor a RNA n the central nervous system. Am J Pathol 144:659-666.
53. Pani A, Marongiu ME (2000) Anti-HIV integrase drugs: How far from the shelf? Curr Pharmac Des 6:569-584.
54. Portegies P, de Gans J, Lange JM, Derix MM, Speelman H, Bakker M, Danner SA, Goadsmit G (1989) Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. British Med J 299:819-821.
55. Price RW (1996) Neurological complications of HIV infection. Lancet 348:445-452.
56. Rolinski B, Bogner JR, Wintergerst U, Goebel FD (1997) Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1 infected patients. J AIDS Hum Retrovirol 15:192-197.
57. Rosenblum LL, Patton G, Grigg AR, Frater AJ, Cain D, Erlwein O, Hill CL, Clarke JR, McClure MO (2001) Differential susceptibility of retroviruses to nucleoside analogues. Antivir Chem Chemother 12:91-97.
58. Rusconi S, Catamancio S, Sheridan F, Parker D (2000) A genotypic analysis of patients receiving zidovudine with either lamivudine, didanosine or zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215. J Clin Virol 19:135-142.
59. Sacktor NC, Lyles RH, Skolasky RL, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (1999) Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 52:1640-1647.
60. Shafer RW, Vuitton DA (1999) Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed & Pharmacother 53:73-86.
61. Sidtis JJ, Gatsonis C, Price R, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Keiburtz K et al (1993) Zidovudine treatment of AIDS dementia complex: results of a placebo controlled trial. Ann Neurol 33:343-349.
62. Sommadossi JP (1998) Pharmacological considerations in antiretroviral therapy. Antivir Ther 3 suppl 4:9-12.
63. Stahl L, Martin C, Svensson JO, Sonnerborg (1997) Indinavir in cerebrospinal fluidof HIV-1 infected patients. Lancet 350:1823.
64. Suarez S, Baril L, Stankoff B, Khellaf M, Dubios B, Lubetzki C, Bricaire F, Hauw JJ (2001) Outcome of patients with HIV-1 related cognitive impairment on highly active antiretroviral therapy. AIDS 15:195-200.
65. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S (2002) Inhibitors of HIV-1 reverse transcriptase and integrase: classic and emerging therapeutical approaches. Curr Pharm Des 8 :595-614.
66. Tashima KT (1998) Cerebrospinal fluid levels of antiretroviral medications. JAMA 280:879-880.
67. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1 infected patients receiving combination therapy. J Infect Dis 180:862-864.
68. Thomas SA, Segal MB (2001) Transport characteristics of the anti-human immunodeficiency virus ucleoside analog abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Therap 298:947-953.
69. Thomas SA, Segal MB (1998) The transport of the anti-HIV drug, 2',3'-didehydro-3'-deoxythymidine (D4T), across the blood brain and blood-cerebrospinal fluid barriers. British J Pharmacol 125:49-54.
70. Thomas SA, Segal MB (1997) The passage of azidodeoxythymidine into and within the cenral nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Therap 281:1211-1218.
71. Tozzi V, Balestra P, Galgani S (1999) Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS 13:1889-1897.
72. UNAIDS-WHO (2001) AIDS epidemic update. Joint United Nations Programme on HIV/AIDS, 1-22.
73. Vago L, Castagna A, Lazzarin A, Traattoni G, Cinque P and Costanzi G (1993) Reduced requency of HIV-induced brain lesions in AIDS treated with zidovudine. J AIDS 6:42-45.
74. Wiley C, Achim C, Christopherson C, Kidane Y, Kwok S, Masliah E, Mellors J, Radhakrishnan L, Wang G, Soontornniyomkij V (1999) HIV mediates a productive infection of the brain. AIDS 13:2055-2059.